The iQ Group Global continued its commitment to unearthing cutting edge research in biosciences by supporting the Diabetes Australia Research awards last month.
The awards, presented at NSW Parliament House on July 19, honour the people and institutions behind the research contributing to the prevention, management and cure for all types of diabetes.
Diabetes Australia President, the Hon. Barry O’Farrell, and CEO Diabetes NSW & ACT Sturt Eastwood awarded recipients for research excellence. Leading pharmacist and advocate John Bell AM was awarded the Sir Kempson Maddox Award, which recognizes a person who has made a significant and lasting contribution to the field of diabetes.
Mr Bell had shown an outstanding commitment to the pharmaceutical profession and to the health and wellbeing of the community, Mr Eastwood said.
“[John’s] work as an educator, advisor to local and international government and industry, and helping the man in the street better understand health issues through his radio program, have and will continue to make a significant difference to the lives of many thousands of people. It has been a pleasure to work closely beside John on the Board of Diabetes NSW & ACT and he is definitely a worthy recipient of the 2019 Sir Kempson Maddox Award,” he said.
Dr George Syrmalis, CEO of The iQ Group Global, delivered a keynote speech at the ceremony, congratulating the award winners.
“What starts here changes the world. These words drive us at The iQ Group Global in our relentless pursuit to find, fund and develop the medicines of tomorrow for the people who need them most, and I can’t think of a better way to describe the impact that the research from tonight’s Diabetes Australia Research Trust Awards will have on the world,” Dr Syrmalis said.
In Australia, more than 1.8 million of 425 million people globally are living with diabetes. To find out more, visit Diabetes Australia.